Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.

Annals of neurology·2026
Same author

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Specific HLA-DRB1 Alleles Associate With Anti-Caspr1 and Anti-CNTN1 Autoantibodies in Autoimmune Nodopathies.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.

Brain : a journal of neurology·2026
Same author

Comprehensive neuropsychological assessment and FDG-PET imaging in patients with RFC1-related disorder.

Parkinsonism & related disorders·2026
Same author

Live Attenuated Measles-Mumps-Rubella and Varicella Vaccinations and Multiple Sclerosis Activity.

JAMA network open·2026
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Fingolimod for relapsing multiple sclerosis: an update.

Alejandro Horga1, Joaquín Castilló, Xavier Montalban

  • 1Multiple Sclerosis Centre of Catalonia (CEM-Cat), Vall d'Hebron University Hospital, Passeig Vall d'Hebron, 119-129, 08035 Barcelona, Spain. ahorga@cem-cat.org

Expert Opinion on Pharmacotherapy
|April 7, 2010
PubMed
Summary
This summary is machine-generated.

Fingolimod, an oral sphingosine-1-phosphate (S1P) receptor modulator, effectively reduces relapse rates and disease activity in relapsing multiple sclerosis (MS). While generally safe, potential adverse events require careful monitoring, with 0.5 mg offering a favorable risk-benefit profile.

Related Experiment Videos

Last Updated: Jun 14, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a leading cause of neurological disability, characterized by CNS inflammation and demyelination.
  • Current disease-modifying therapies for MS present limitations in convenience, safety, and efficacy.
  • Fingolimod is an investigational oral sphingosine-1-phosphate (S1P) receptor modulator for MS treatment.

Purpose of the Study:

  • To review the mechanism of action, pharmacology, and clinical trial data for fingolimod in relapsing MS.
  • To provide a comprehensive overview of fingolimod's properties and efficacy.
  • To assess the safety and risk-benefit profile of fingolimod.

Main Methods:

  • Review of clinical trial data, including Phase II and pivotal Phase III studies.
  • Analysis of fingolimod's mechanism of action, focusing on S1P receptor modulation and lymphocyte egress inhibition.
  • Evaluation of pharmacokinetic and pharmacodynamic properties.

Main Results:

  • Fingolimod demonstrated superior efficacy in reducing relapse rates compared to placebo and intramuscular interferon-beta-1a.
  • MRI measures of disease activity were significantly reduced with fingolimod treatment.
  • Fingolimod also showed a reduced risk of disability progression versus placebo.

Conclusions:

  • Fingolimod is an effective treatment for relapsing MS, offering significant reductions in disease activity and disability progression.
  • Adverse events include bradycardia, infections, elevated liver enzymes, hypertension, and macular edema.
  • The 0.5 mg dose of fingolimod appears to provide an optimal risk-benefit balance.